S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
S&P 500   3,901.36 (+0.01%)
DOW   31,261.90 (+0.03%)
QQQ   288.68 (-0.31%)
AAPL   137.59 (+0.17%)
MSFT   252.56 (-0.23%)
FB   193.54 (+1.18%)
GOOGL   2,178.16 (-1.34%)
AMZN   2,151.82 (+0.25%)
TSLA   663.90 (-6.42%)
NVDA   166.94 (-2.51%)
BABA   86.79 (-1.03%)
NIO   16.44 (-1.32%)
AMD   93.50 (-3.28%)
CGC   5.52 (-5.96%)
MU   68.90 (-0.72%)
T   20.40 (+0.94%)
GE   75.25 (-0.65%)
F   12.50 (-2.72%)
DIS   102.42 (-0.70%)
AMC   12.03 (-8.03%)
PFE   52.47 (+3.59%)
PYPL   80.54 (-0.91%)
NFLX   186.35 (+1.56%)
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$57.88
+0.15 (+0.26%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$55.55
$59.85
50-Day Range
$43.00
$65.64
52-Week Range
$28.40
$66.00
Volume
873,838 shs
Average Volume
1.13 million shs
Market Capitalization
$5.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.28
30 days | 90 days | 365 days | Advanced Chart
Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies logo

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
512
Year Founded
N/A

Sales & Book Value

Annual Sales
$83.80 million
Book Value
$8.40 per share

Profitability

Net Income
$-284.13 million
Net Margins
-294.89%
Pretax Margin
-294.89%

Debt

Price-To-Earnings

Miscellaneous

Free Float
81,873,000
Market Cap
$5.46 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/20/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

616th out of 1,420 stocks

Pharmaceutical Preparations Industry

284th out of 679 stocks

Analyst Opinion: 1.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -













Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies
or view top-rated stocks.

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Intra-Cellular Therapies
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings data on Tuesday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.14. The biopharmaceutical company had revenue of $35 million for the quarter, compared to analyst estimates of $33.52 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 294.89%. The business's revenue for the quarter was up 120.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) EPS.
View Intra-Cellular Therapies' earnings history
.

What price target have analysts set for ITCI?

7 brokers have issued twelve-month price targets for Intra-Cellular Therapies' shares. Their forecasts range from $40.00 to $70.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $60.43 in the next year. This suggests a possible upside of 4.4% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?
Intra-Cellular Therapies' management team includes the following people:
  • Dr. Sharon Mates Ph.D., Co-Founder, Chairman, CEO & Pres (Age 69, Pay $2.25M)
  • Mr. Lawrence J. Hineline CPA, CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec. (Age 66, Pay $791.01k) (LinkedIn Profile)
  • Mr. Michael I. Halstead J.D., Exec. VP, Gen. Counsel & Sec. (Age 49, Pay $1.08M)
  • Dr. Suresh K. Durgam M.D., Exec. VP & Chief Medical Officer (Age 53, Pay $1.03M) (LinkedIn Profile)
  • Mr. Mark Neumann, EVP & Chief Commercial Officer (Age 59, Pay $1.01M) (LinkedIn Profile)
  • Dr. Robert E. Davis Ph.D., Sr. VP & Chief Scientific Officer (Age 71)
  • Mr. Juan Fernando Sanchez, VP of Corp. Communications & Investor Relations (Age 51)
  • Ms. Karen Patruno Sheehy Esq., Sr. VP & Chief Compliance Officer (Age 60)
  • Dr. Michael Olchaskey, Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi, Sr. VP of Market Access, Policy & Gov. Affairs
What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.26%), Wasatch Advisors Inc. (7.93%), BlackRock Inc. (6.86%), Wellington Management Group LLP (4.31%), Bellevue Group AG (3.64%) and Lord Abbett & CO. LLC (2.10%). Company insiders that own Intra-Cellular Therapies stock include Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies
.

Which institutional investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., TimesSquare Capital Management LLC, Bellevue Group AG, Lord Abbett & CO. LLC, DCF Advisers LLC, Rhenman & Partners Asset Management AB, Clearbridge Investments LLC, and Nicholas Investment Partners LP. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies
or view top insider-selling stocks.

Which institutional investors are buying Intra-Cellular Therapies stock?

ITCI stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Victory Capital Management Inc., Vanguard Group Inc., BlackRock Inc., Hood River Capital Management LLC, Invesco Ltd., Polar Capital Holdings Plc, and Suvretta Capital Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies
or or view top insider-buying stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $57.88.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $5.46 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284.13 million in net income (profit) each year or ($3.630010) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 512 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.

This page was last updated on 5/20/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.